Results: In the studied period of time, 93 patients received a continuous flow LVAD. Six patients with LVAD implantation who presented with Gastrointestinal bleeding (GIB) were placed on Danazol. One patient discontinued the drug because of side effects. In the remaining five patients, mean time to initial GIB after LVAD implant was 9.6 months. Only one patient was started on Danazol after the first episode of GIB, while the rest of them had recurrent events. The average number of episodes of GIB was 3.4. Before Danazol, mean time in between hospital readmissions related to recurrent GIB was 1.5 months. After the patients were initiated on Danazol for treatment of GIB, mean time in between hospital readmissions related to recurrent GIB after initiation of Danazol increased to 4.4 months. Only one patient experienced another episode of GIB on Danazol. The four that did not remained free of GIB for an average of 2.9 months. After that, two were transplanted and the other two continue to be on LVAD support. Conclusion: Danazol may increase the intervals between the episodes of GIB and prevent the recurrent episode in some patient with LVADS. Danazol should be considered as a treatment in patients with LVAD and GIB.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.